Nabil Saleem

Dr. Nabil Saleem

orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2016 in Aquatic Toxicology
Verified
Journal Article
Closed access
LWLarissa Williams
Larissa Williams
BLBriony A. Lago
Briony A. Lago
Andrew McArthurAndrew McArthur
Andrew McArthur
ARAmogelang R. Raphenya
Amogelang R. Raphenya
NPNicholas Pray
Nicholas Pray
JSJordan A. Shavit
Jordan A. Shavit

11 June 2021 in Medicine
Verified
Journal Article
Open access
NSNabil Saleem
Nabil Saleem
LMLesley S Miller
Lesley S Miller
ADAlia S Dadabhai
Alia S Dadabhai
ECEmily J Cartwright
Emily J Cartwright
We assessed the performance characteristics of the Fibrosis-4 (FIB-4) score in a veteran population with chronic hepatitis C virus (HCV) infection and used vibration controlled transient elastography (VCTE) as the gold standard. All VCTE studies were performed by a single operator on United States veterans with HCV infection presenting for care at the Atlanta VA Medical Center (AVAMC) over a 2 year period. VCTE liver stiffness measurements (LSM) were categorized as cirrhotic if LSM was >12.5 kPa and non-cirrhotic if LSM was ≤12.5 kPa. FIB-4 scores ≤3.25 were considered non-cirrhotic and scores >3.25 were considered cirrhotic. Sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) were calculated for the FIB-4 score. A second analysis was done which identified and excluded indeterminate FIB-4 scores, defined as any value between 1.45 and 3.25. When FIB-4 was used to screen for liver cirrhosis using VCTE as the gold standard, sensitivity was 42%, specificity was 88%, PPV was 62%, and NPV was 76%. When indeterminate FIB-4 scores were excluded from the analysis, sensitivity was 95%, specificity was 61%, PPV was 62%, and NPV was 94.4%. In a veteran population with chronic HCV infection, we found the sensitivity of the FIB-4 score to be unacceptably low for ruling out liver cirrhosis when using a binary cutoff at 3.25. Using a second staging method like VCTE may be an effective way to screen for liver cirrhosis in persons with chronic HCV, especially when the FIB-4 score is in the indeterminate range.

30 October 2020 in BMJ Case Reports
Verified
Journal Article
Closed access
PDF file
NSNabil Saleem
Nabil Saleem
WDWilliam J Devan
William J Devan
DPDaniel R Pitts
Daniel R Pitts
GVGraham T VerLee
Graham T VerLee
There are few reports of radiation associated colorectal–genitourinary tract (CRGU) fistulae causing Fournier’s gangrene (FG). We describe a case of FG in a patient with possibly two CRGU fistulae in the context of previous high-dose brachytherapy and external beam radiation therapy for prostate cancer. Unfortunately, CRGU fistulae are not well classified as significant risk factors for the development of FG. Our case demonstrates the rationale for maintaining a broad differential in patients presenting with recurrent urinary tract symptoms or necrotising soft tissue infections to include undiagnosed fistulae.

2 October 2026 in Cancers
Verified
Journal Article
Open access
PDF file
ESEmily Catherine Sullivan
Emily Catherine Sullivan
NSNabil Saleem
Nabil Saleem
AHAreeba Ashraf Hashmi
Areeba Ashraf Hashmi
KKKristopher Knight
Kristopher Knight
ABAustre Y Schiaffino Bustamante
Austre Y Schiaffino Bustamante
SRSunil Raikar
Sunil Raikar
Background: Acute myeloid leukemia (AML) remains the deadliest form of leukemia in children and adults despite therapeutic advances in recent decades. Chimeric antigen receptor (CAR) T-cell therapy is one such therapeutic approach that has been explored preclinically and clinically in AML; however, its efficacy is limited by antigen heterogeneity. To overcome this roadblock, we propose a dual-targeting CAR T-cell strategy, targeting the AML-associated antigens CD33 and CD70. Methods: To recapitulate tumor heterogeneity, we genetically edited the AML cell line Molm-13 using CRISPR-Cas9 to generate distinct sublines, namely CD33+/CD70−, CD33−/CD70+, and CD33+/CD70+. Two dual-targeting CAR T-cell approaches were developed: a “pooled” product, in which CAR T cells directed towards CD33 or CD70 are combined and co-administered, and a “co-transduced” product, wherein one population of T cells is transduced with both CD33-CAR- and CD70-CAR-encoding viral vectors. Results: Pooled and co-transduced products demonstrated potent cytotoxicity against all Molm-13 populations, whereas single-antigen CAR approaches were not as effective when their respective target antigen was absent. Mice engrafted with CD33/CD70 heterogeneous Molm-13 cells were treated with pooled or co-transduced CD33/CD70 CAR T cells. Both groups exhibited a significant survival advantage over the untreated group, with the co-transduced approach showing a statistically significant advantage over the pooled group. Conclusions: In summary, engineering one T cell to express both CARs yielded superior cytotoxicity when targeting a heterogeneous AML blast population.

1 January 2026 in Case Reports in Pediatrics
Verified
Journal Article
Open access
NSNabil Saleem
Nabil Saleem
PSPamela B. Sylvestre
Pamela B. Sylvestre
FCFranklin L. Chien
Franklin L. Chien
RGRaul S. Gonzalez
Raul S. Gonzalez
JVJose E. Velázquez Vega
Jose E. Velázquez Vega
SMSarah Mitchell
Sarah Mitchell
Yolk sac tumors, a subset of malignant germ cell tumors originating from gonadal germ cells, most often present as ovarian or testicular tumors in adolescents, sometimes in combination with different types of histology as a mixed malignant germ cell tumor. We describe a female toddler presenting with severe iron deficiency anemia who was found to have a gastric pure yolk sac tumor. Pure yolk sac tumor of the stomach has rarely been reported and is even less frequent in the pediatric population. Our review of the medical literature found 12 case reports of gastric pure yolk sac tumor, of which only 1 was in a child, a 3‐year‐old male. Our patient underwent subtotal gastrectomy and received adjuvant systemic chemotherapy and is tumor‐free at 3 years following surgery. This is the first reported case of a gastric pure yolk sac tumor in a pediatric female, brought to clinical attention due to significant gastrointestinal blood loss.